loading min read

Moving finance upstream: A new mandate for life sciences CFOs

Learn why life sciences CFOs should move finance upstream to improve transaction readiness, decision-making, and strategic flexibility.

For growth-stage life sciences companies, financial complexity increasingly begins before a transaction is executed.

Companies are pursuing new business models, strategic collaborations, alternative sources of capital, and transactions to fund innovation and accelerate growth. These decisions can blur the lines between strategy, finance, accounting, and operations.

The implication for the Office of the CFO is clear: finance can no longer simply account for business decisions after they happen. It needs to help shape them.

Complex transactions require an integrated finance perspective

Consider two recent transactions.

AstraZeneca's 2026 collaboration with insitro included $40 million upfront and up to approximately $1.46 billion in potential milestones. Spero Therapeutics, meanwhile, entered into an approximately $105 million royalty financing tied to UTEBZI, its GSK-licensed asset.

The structures are different, but the finance challenge is similar. Headline transaction value tells only part of the story.CFOs need to understand how milestones, contractual rights and obligations, probability, timing, and alternative structures affect expected economics, liquidity, financial reporting, and ultimately the story communicated to boards and investors.

That requires an integrated perspective before terms are finalized.

    • FP&A can model scenarios and liquidity implications.
    • Valuation can inform the economics of contingent payments and financial instruments.
    • Technical accounting can evaluate how the substance of an arrangement affects classification, recognition, measurement, and presentation.

The objective is not simply to get the accounting right. It is to understand how different structures affect the business before committing to them.

Finance needs a seat at the table before terms are set

There are consequences when contractual economics and financial reporting diverge. Public-company restatements have demonstrated how side agreements, return rights, contingent payment terms, and other provisions that change the substance of an arrangement can contribute to premature revenue recognition, control deficiencies, delayed filings, and significant remediation costs.

Earlier finance involvement creates an opportunity to identify these issues before they become accounting issues.

Readiness creates optionality

The same principle extends beyond individual transactions.

Life sciences M&A is gaining momentum, increasing the importance of being ready before an investor or buyer appears. Yet many companies begin preparing only when a transaction becomes imminent.

By then, important decisions about accounting policies, forecasts, controls, systems, and data have already been made.

A more effective model is continuous readiness.

That means maintaining audit-ready financial information, defensible forecasts, scalable processes and controls, and reliable clinical and operational data. For companies considering an investment or acquisition by a larger industry participant, early diligence can identify accounting, tax, operational, and data issues before buyers do.

The payoff extends beyond compliance. Readiness can accelerate diligence, reduce execution risk, strengthen management's negotiating position, and preserve strategic flexibility.

The CFO’s new mandate

For life sciences CFOs, the mandate is increasingly clear: move finance upstream.

Technical accounting, FP&A, valuation, finance operations, audit readiness, and transaction diligence need to operate as an integrated capability, before the next transaction dictates the timetable.

Related services

Our solutions are tailored to each client’s strategic business drivers, technologies, corporate structure, and culture.

Receive CohnReznick insights and event invitations on topics relevant to your business and role.
Subscribe
Any advice contained in this communication, including attachments and enclosures, is not intended as a thorough, in-depth analysis of specific issues. Nor is it sufficient to avoid tax-related penalties. This has been prepared for information purposes and general guidance only and does not constitute legal or professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice specific to, among other things, your individual facts, circumstances and jurisdiction. No representation or warranty (express or implied) is made as to the accuracy or completeness of the information contained in this publication, and CohnReznick, its partners, employees and agents accept no liability, and disclaim all responsibility, for the consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.

"CohnReznick" is the brand name under which CohnReznick LLP and CohnReznick Advisory LLC and their respective subsidiaries provide professional services. CohnReznick LLP and CohnReznick Advisory LLC (and their respective subsidiaries) practice in an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable law, regulations, and professional standards. CohnReznick LLP is a licensed CPA firm that provides attest services to its clients. CohnReznick Advisory LLC provides tax and business consulting services to its clients. CohnReznick Advisory LLC and its subsidiaries are not licensed CPA firms.

member of nexia

CohnReznick is a member of Nexia, a leading, global network of independent accounting and consulting firms. Please see the “Member firm disclaimer (Opens a new window)” for further details.

© 2026 CohnReznick Advisory LLC, All Rights Reserved.